October 16, 2026 · Patent expires April 17, 2034

Tukysa (Tucatinib): The 2032-2038 Generic Opportunity Window

Tukysa (tucatinib, Seagen/Pfizer, NDA 213411) generated 80M in 2024 revenue. The LOE opportunity window spans from the 2032 solid dispersion formulation patent (US 9,457,093) through the 2034 core substance patent (US 8,648,087) and 2038 method-of-use coverage (US 11,207,324). Commercial status: 100% brand-only in the US with active API and finished formulation positioning by Natco, Zydus, MSN, and Dr. Reddys.

What we do

We track expirations like this continuously

This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.